Salvatore, Lisa
 Distribuzione geografica
Continente #
NA - Nord America 2.643
AS - Asia 1.617
EU - Europa 1.341
SA - Sud America 304
AF - Africa 42
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 5.949
Nazione #
US - Stati Uniti d'America 2.548
SG - Singapore 691
DE - Germania 450
IT - Italia 324
CN - Cina 294
BR - Brasile 243
VN - Vietnam 165
BD - Bangladesh 158
SE - Svezia 127
FR - Francia 116
IN - India 85
GB - Regno Unito 74
FI - Finlandia 65
CA - Canada 51
HK - Hong Kong 46
IE - Irlanda 42
JP - Giappone 39
ID - Indonesia 34
AT - Austria 29
AR - Argentina 26
MX - Messico 25
PL - Polonia 24
KR - Corea 22
RU - Federazione Russa 16
ZA - Sudafrica 16
TR - Turchia 14
NL - Olanda 13
IQ - Iraq 12
EC - Ecuador 11
ES - Italia 11
VE - Venezuela 9
CZ - Repubblica Ceca 8
JM - Giamaica 8
LT - Lituania 8
PK - Pakistan 8
IR - Iran 7
RO - Romania 7
SA - Arabia Saudita 7
BE - Belgio 6
CI - Costa d'Avorio 6
UA - Ucraina 6
CO - Colombia 4
DZ - Algeria 4
KZ - Kazakistan 4
PY - Paraguay 4
UZ - Uzbekistan 4
AL - Albania 3
CH - Svizzera 3
GE - Georgia 3
HN - Honduras 3
IL - Israele 3
KE - Kenya 3
PE - Perù 3
TH - Thailandia 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CL - Cile 2
EG - Egitto 2
MA - Marocco 2
MY - Malesia 2
NG - Nigeria 2
OM - Oman 2
PH - Filippine 2
PT - Portogallo 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UY - Uruguay 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BW - Botswana 1
CR - Costa Rica 1
DM - Dominica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
JO - Giordania 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TM - Turkmenistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.949
Città #
Ashburn 724
Singapore 417
San Jose 187
Los Angeles 184
New York 157
Chandler 152
Rome 98
Buffalo 87
Beijing 68
Ho Chi Minh City 62
Hyderabad 57
Hefei 54
Hong Kong 45
Helsinki 44
Lauterbourg 43
Santa Clara 42
Dublin 41
Hanoi 40
The Dalles 40
Tokyo 39
Council Bluffs 37
Munich 37
Chicago 36
Dallas 36
Frankfurt am Main 30
Milan 29
Jakarta 26
Boston 25
São Paulo 25
Toronto 25
Vienna 23
Seoul 21
London 20
Orem 19
Wilmington 18
Houston 17
Marseille 17
Princeton 16
Charlotte 14
Kent 14
Mexico City 14
Warsaw 14
Lappeenranta 13
Cattolica 12
Johannesburg 12
Boardman 11
Denver 11
Nuremberg 11
Pasadena 11
St Louis 11
Bexley 9
Poplar 9
Atlanta 8
Columbus 8
Falkenstein 8
Haiphong 8
Hải Dương 8
Montreal 8
Moscow 8
Paris 8
Seattle 8
Stockholm 8
Turku 8
Amsterdam 7
Bari 7
Bremen 7
Curitiba 7
Hamburg 7
Naples 7
Palermo 7
Portsmouth 7
Rio de Janeiro 7
Salt Lake City 7
San Mateo 7
Abidjan 6
Brooklyn 6
Buenos Aires 6
Kingston 6
Manchester 6
Phoenix 6
Roubaix 6
Washington 6
Ankara 5
Baghdad 5
Brasília 5
Brussels 5
Da Nang 5
Düsseldorf 5
Elk Grove Village 5
Florence 5
Kampong Loyang 5
Mumbai 5
Querétaro 5
Redmond 5
Shanghai 5
Biên Hòa 4
Bologna 4
Brdo 4
Chennai 4
Concord 4
Totale 3.502
Nome #
Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection 618
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers 611
THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy 518
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center 197
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis 190
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 168
Management of single pulmonary metastases from colorectal cancer: State of the art 161
Clinical, pathological and prognostic features of rare braf mutations in metastatic colorectal cancer (Mcrc): A bi-institutional retrospective analysis (rebus study) 157
Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies 146
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies 143
The role of the multidisciplinary tumor board (MDTB) in the assessment of pancreatic cancer diagnosis and resectability: A tertiary referral center experience 136
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: Lessons from the AtezoT RIBE study 136
The Impact of a Multidisciplinary Tumor Board (MDTB) in the Management of Colorectal Cancer (CRC) 134
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial 133
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report 132
Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies 129
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 128
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer 124
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 122
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 122
MetaLiverCat: the NAFLD/NASH multidisciplinary board at Fondazione Policlinico Gemelli IRCCS 121
Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis 119
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients 119
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 118
The impact of the histological classification of ampullary carcinomas on long-term outcomes after pancreaticoduodenectomy: a single tertiary referral center evaluation 114
Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis 112
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab with or Without Atezolizumab for Patients with Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 110
Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis 106
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C 99
PTEN in colorectal cancer: Shedding light on its role as predictor and target 93
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 92
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 92
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience 90
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 87
Activity and safety of cetuximab plus modified folfoxiri followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer a randomized phase 2 clinical trial 77
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 72
Management of patients with early-stage colon cancer: Guidelines of the Italian Medical Oncology Association 63
Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance 60
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 55
Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice 8
Fluoropyrimidine Cardiotoxicity: Role of Uridine Triacetate and Pharmacogenomic Insights from a Case of 5-FU-Induced Cardiogenic Shock 4
Prognostic impact of Geriatric 8 and comprehensive geriatric assessment in older patients with advanced pancreatic ductal adenocarcinoma 4
Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice 4
Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer 3
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis 3
MRI-based radiomics predicts the pathologic response of colorectal liver metastases to systemic therapy: A multicenter study 3
Molecular and Clinical Profile of a RET-Rearranged Colorectal Cancer With Prolonged Response to Platinum Therapy and Subsequent Targeted Treatment With Selpercatinib 1
Totale 6.034
Categoria #
all - tutte 19.883
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.883


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022135 8 2 0 13 5 3 2 16 4 11 37 34
2022/2023435 42 46 35 68 36 53 26 27 42 14 16 30
2023/2024755 10 50 27 22 17 38 244 255 2 14 37 39
2024/2025921 12 11 57 32 53 40 73 31 102 120 235 155
2025/20263.615 291 117 207 459 455 452 330 149 191 153 192 619
2026/2027143 143 0 0 0 0 0 0 0 0 0 0 0
Totale 6.034